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Abstract
Transcription factors play a crucial role in regulating differentiation processes during human life and are important in
disease. The basic helix-loop-helix transcription factors Tal1 and Lyl1 play a major role in the regulation of gene
expression in the hematopoietic system and are involved in human leukemia. Tal2, which belongs to the same family
of transcription factors as Tal1 and Lyl1, is also involved in human leukaemia. However, little is known regarding the
expression and regulation of Tal2 in hematopoietic cells. Here we show that Tal2 is expressed in hematopoietic cells
of the myeloid lineage. Interestingly, we found that usage of the Tal2 promoter is different in human and mouse cells.
Two promoters, hP1 and hP2 drive Tal2 expression in human erythroleukemia K562 cells, however in mouse RAW
cells  only  the  mP1  promoter  is  used.  Furthermore,  we  found  that  Tal2  expression  is  upregulated  during
oesteoclastogenesis. We show that Tal2 is a direct target gene of the myeloid transcription factor PU.1, which is a
key transcription factor for osteoclast gene expression. Strikingly, PU.1 binding to the P1 promoter is conserved
between mouse and human, but PU.1 binding to P2 was only detected in human K562 cells. Additionally, we provide
evidence that Tal2 influences the expression of the osteoclastic differentiation gene TRACP. These findings provide
novel insight into the expression control of Tal2 in hematopoietic cells and reveal a function of Tal2 as a regulator of
gene expression during osteoclast differentiation.
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Introduction
The closely related basic helix-loop-helix transcription factors
Tal1 (SCL1), Tal2 and Lyl1 are important regulators of normal
development and differentiation. Tal1 is essential for primitive
hematopoiesis and plays a role as a regulator of erythrocytic/
megakaryocytic gene expression in the adult [1]. Unlike Tal1,
the  closely  related  Lyl1  protein  is  not  needed  for  early
hematopoietic  development  [2,3]  and  may  have  overlapping
and independent functions with Tal1 in gene regulation [4].
The  Tal2  protein  consists  of  an  N-terminal  bHLH-domain,
which  is  highly  similar  to  Tal1  and  Lyl1  and  has  a  short  C-
terminus. However, the Tal2 protein is smaller than Tal1 and
Lyl1, because it lacks N-terminal transactivation or repression
domains.  Despite  these  differences,  Tal1,  Lyl1  and  Tal2  are
associated with T-cell acute lymphoblastic leukaemia (T-ALL)
[5]. Here, chromosomal translocations lead to the misregulation
of the transcription factors, which might be causally connected
to  the  disease  [6,7,8,9,10].  Tal2  was  found  at  the  t(7;9)
(q35;q34) chromosomal translocations associated with T-ALL
[6]. In contrast to its closely related family members Tal1 and
Lyl1, Tal2 expression was not described in the hematopoietic
system during normal hematopoietic differentiation. However,
in  the  testis,  the  brain  of  mice  and  the  lateral  floor  plate  of
zebrafish Tal2 is expressed [11,12,13]. Targeted disruption of
Tal2 in the mouse leads to developmental defects in the central
nervous system and to early death after birth [11]. In this study
no overt defects in hematopoiesis were found in Tal2 -/- mice.
Recently, it was reported that Tal2 is over expressed in non-
small cell lung cancer tissue compared to normal lung tissue
[14]. Furthermore, Tal2 expression was connected to human
epithelial ovarian cancer [15]. This raises the question if Tal2 is
causally  connected  to  other  cancer  types  than  T-cell
leukaemia.
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e76637Although Tal2 has an important function in development and
leukemia, little is known regarding the regulation of Tal2 and its
expression in different cell types. Recently, we showed that the
related  transcription  factor  Tal1  plays  a  role  in  osteoclast
differentiation [16]. This observation prompted us to examine
the  expression  of  Tal2  during  osteoclast  differentiation.
Osteoclasts  are  multinucleated  bone  resorbing  cells,  which
differentiate  from  a  myeloid  progenitor  upon  stimulation  with
the  cytokines  macrophage-colony-stimulating  factor  (M-CSF)
and  receptor  activator  of  NF-kB  ligand  (RANKL)
[17,18,19,20,21,22,23].  Downstream  of  these  cytokines
osteoclast gene expression and differentiation is regulated by
transcription  factors  such  as  Tal1,  PU.1,  MITF,  AP1,  MafB,
CEBPbeta  and  NFATC  [16,24,25,26,27,28].  Deregulation  of
osteoclast function plays a major role in human disease like
osteoporosis, multiple myeloma and metastatic breast cancer
[17,18,29,30].
In this study we found that Tal2 expression is upregulated
during  M-CSF/RANKL  induced  osteoclastogenesis.
Furthermore  we  detected  Tal2  expression  in  the  human
erythroleukaemia  cell  line  K562  and  found  that  Tal2  is
regulated  from  two  alternative  promoters  in  human  cells.
Although Tal2 expression regulation might be different between
mouse and human, binding of PU.1 to Tal2 regulatory elements
is conserved.
Materials and Methods
Bioinformatics
Analysis of the Tal2 5’-region for transcription factor binding
sites was performed using TESS [31]. Evolutionary conserved
regions between different species were defined with the help of
the  ECR-browser  [32]  using  standard  settings.  Expression
database analysis of mouse Tal2 was performed with BioGPS
[33].  Repeat  elements  in  the  5’  region  of  human  Tal2  were
determined  using  the  repeatmasker  software  (Smit,  AFA,
Hubley,  R  &  Green,  P.  RepeatMasker  Open-3.0.  1996-2010
http://www.repeatmasker.org).
Cell culture and mice
RAW264.7, HEK293 and HeLa cells (ATCC) were cultured in
Dulbecco’s modified eagle medium (DMEM; Gibco), K562 and
U937  (ATCC)  cells  were  cultured  in  RPMI  medium  (Gibco),
both  media  supplemented  with  10%  fetal  calf  serum  (FCS;
PAA),  2  mM  L-glutamine  and  1%  penicillin/streptomycin
(Gibco).  To  differentiate  RAW264.7  towards  the  osteoclast
lineage,  cells  were  cultured  in  the  presence  of  30  ng/ml
recombinant  murine  RANK-L-TEC  (R&D  Systems).  For
differentiation  of  U937  cells  were  first  treated  with  0.1  µg/ml
TPA to induce monocytic differentiation, after 2 days cells were
treated with 50 ng/ml recombinant M-CSF (R&D Systems) and
100  ng/ml  recombinant  RANK-L-TEC  for  additional  three/six
days. To obtain bone marrow derived monocytes/macrophages
(BMM) bone marrow cells were prepared from BL/6 mice as
previously described [16].
RNA isolation and real-time RT-PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen).
cDNA  was  synthesized  using  the  Omniscript  reverse
transcriptase (Qiagen). Quantitative PCR was performed on a
LightCycler  480  (Roche)  using  SYBR-Green  PCR  MasterMix
(Eurogentec) and the following primers: human Tal2 forward 5
´-  AAAGCCTGCAACAAACGGGA-3´  and  reverse  5´-
TGGACCAGGTGAAGGAACCT  -3´;  murine  Tal2  forward  5´-
TGCATCAAACAGGAGTCGCT-3´  and  reverse  5´-
GGAAGGAACTCGGTAGTCAT-3´; human TRACP forward 5´-
GGACTGAAGGGACTCCTGAAT-3´  and  reverse  5´-
GGTCCCTGAGCCTTTATTCC-3´; murine TRACP forward 5´-
GACAAGAGGTTCCAGGAGACC-3´  and  reverse  5´-
GGGCTGGGGAAGTTCCAG-3´; murine DC-STAMP forward 5
´-TGTATCGGCTCATCTCCTCCAT-3´  and  reverse  5´-
GACTCCTTGGGTTCCTTGCTT-3´;  murine  Cathepsin  K
forward 5´-ACAGCAGGATGTGGGTGTTCA-3´ and reverse 5´-
GCCGAGAGATTTCATCCACCT-3´; murine MMP9 forward 5´-
ACGACATAGACGGCATCCA-3´  and  reverse  5´-
GCTGTGGTTCAGTTGTGGTG-3´. Relative amounts of mRNA
were  calculated  by  the  delta-delta-Ct  method  using  murine
GAPDH  forward  5´-TCCACTCATGGCAAATTCAA-3´  and
reverse  5´-TTTGATGTTAGTGGGGTCTCG-3´  or  murine  TBP
forward  5´-GGCGGTTTGGCTAGGTTT-3´  and  reverse  5´-
GGGTTATCTTCACACACCATGA-3´  or  human  GAPDH
forward  5´-GAGTCAACGGATTTGGTCGTATT-3´  and  reverse
5´-GAATTTGCCATGGGTGGAAT-3´ as an internal control.
Luciferase assay
Human and murine promoter sequences were amplified from
genomic DNA. Around 500 bp of the human hP1, hP2 region
and the murine mP1, mP2 region were cloned into the pGL4.10
luciferase  reporter  plasmid  (Promega).  The  human  Tal2
promoter  sequence  was  amplified  from  K562  genomic  DNA.
Constructs of 1600bp, 1030bp and 495bp were generated and
cloned into the pGL4.10 luciferase reporter plasmid (Promega).
Binding  sites  for  PU.1  and  GATA1  in  the  Tal2  promoter
constructs were mutated using the Site Directed Mutagenesis
Kit  (Stratagene).  HEK293  cells  were  transfected  with
Metafecten  (Biontex),  RAW  264.7  and  K562  cells  were
transfected  with  Metafecten  Pro  (Biontex),  U937  cells  were
transfected  with  FuGENE  (Promega)  according  the
manufactures  instruction.  A  CMV-promoter  driven  beta-
galactosidase  vector  was  co-transfected  as  a  transfection
control.  Luciferase  and  beta-galactosidase  activity  was
assayed 48 h after transfection. Firefly luciferase activity was
normalized  to  beta-galactosidase  to  control  for  transfection
efficiency.
Western Blot
Western  blot  was  performed  according  to  standard
procedures  with  an  anti-Tal2  antibody  (Santa  Cruz  sc-46266
and Abcam ab85432) and an anti-Lamin antibody or anti-Actin
antibody (Abcam ab16048 and Santa Cruz sc-1615) as loading
control. The SDS-loading buffer was supplemented with 1 M
Urea for better detection of Tal2.
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Total  RNA  was  isolated  from  RAW264.7,  K562  and  U937
cells using RNeasy mini kit (Qiagen). The 5´-ends of the Tal2
gene  were  identified  using  the  5′-RACE  System  for  rapid
amplification of cDNA ends (Invitrogen). The following primers
were  used:  murine  Tal2-GSP1  (5′-
AGTAGAGTTCTGTCATCC-3′)  and  human  Tal2-GSP1  (5′-
CTAAGGAATGTGGTGGC-3′)  for  cDNA  synthesis,  murine
Tal2-GSP2  (5′-TCATCTGGCAGGCGGGTC-3′)  and  human
Tal2-GSP2 (5′- AGGTTCCTTCACCTGGTCCA-3′) for the first
PCR,  murine  Tal2-GSP3  (5′-
TATAGGATCCGAAAGAGCCCCAGAATGT-3′)  and  human
Tal2-GSP3  (5′-
TATAGGATCCGTAGTTCTCAAGCAGAGTTC-3′)  for  the
nested PCR. The final PCR products contained a SalI and a
BamHI  site  for  cloning  into  the  pIRES-EGFP  vector  (Takara
Bio) and were sequenced.
Knockdown experiments with shRNA
For short hairpin interfering RNA experiments, shRNAs were
cloned into psiRNA (Invivogen). shRNA oligos against murine
Tal1  were  designed  using  the  ‘InvivoGen’s  siRNAWizard’
program  (http://www.sirnawizard.com/design.php).  As  control,
a  nonspecific  shRNA  was  used.  Sequences  targeted  by
shRNAs:  Control  (5’-GTG  ACC  AGC  GAA  TAC  CTG  TT-3’)
and murine Tal2 (5’-GTC GCT GCT CAG GGA AAC AT -3’).
The integrity of the constructs was verified by sequencing.
Chromatin immunoprecipitation
Chromatin  immunoprecipitation  (ChIP)  assays  were
performed as described [34]. Sonicated chromatin from K562
or RAW264.7 cells was incubated with anti-RNAPolII (Abcam,
ab5408),  anti-GATA1  (Santa  Cruz,  sc-1233)  or  anti-PU.1
(SantaCruz,  sc-352).  Normal  IgG  (Santa  Cruz)  was  used  as
control. DNA was amplified using the following primers: human
Tal2  promoter  hP1-forward  5´-
CGGATACGGACTTTCCCAGG-3´  and  hP1-reverse  5´-
CTGGAAAGGGAGCAAGGGAG-3´;  human  Tal2  promoter
hP2-forward  5´-GCGTCACTGATGCCTCGAAAGGT-3´  and
hP2-reverse  5´-AGATGGAAAGAGAAAGGGCCCTCAG-3´;
murine  Tal2  promoter  mP1-forward  5´-
AAGGGGATCTGGAGGTGGCCA-3´  and  mP1-reverse  5´-
CCAAGTGCAGCAGCCAAGGAG-3´;  murine  Tal2  promoter
mP2-forward  5´-GCTAACATTGCAGGTTCTTGGCAG-3´  and
mP2-reverse 5´-TCCAGGTTCCTGCGATGAGAGAGA-3´.
Results
Expression of Tal2
To examine Tal2 expression we pursued a database search
using BioGPS [33]. In this publicly available data set a three
times  higher  expression  of  Tal2  was  detected  in  osteoclasts
and  granulocytic  cells  than  in  macrophages  of  the  mouse
(Figure  1A).  Subsequently,  we  analyzed  Tal2  expression  in
bone marrow derived monocyte macrophage cell (BMM) and
upon  in  vitro  osteoclast  differentiation  of  the  BMM  cells.  We
detected  a  slight  upregulation  of  Tal2  at  day  three  of
differentiation and a 4-fold increase at day six of differentiation
at the mRNA level (Figure 1B), which is in agreement with the
BioGPS data. We also detected increase of Tal2 protein at day
six upon differentiation (Figure 1B). Concomitantly, expression
of  the  osteoclast  differentiation  gene  TRACP  was  increased
(Figure  1C).  Similarly,  we  found  Tal2  upregulation  during
osteoclastic differentiation of the mouse monocyte macrophage
RAW  cell  line  (Figure  1D,E),  when  we  exposed  the  cells  to
osteoclast differentiation conditions. The upregulation of Tal2
and TRACP was also seen in the human U937 cell line under
osteoclast differentiation conditions (Figure 1F,G). Additionally,
we  analyzed  several  cell  lines  of  hematopoietic  and  non-
hematopoietic origin for Tal2 mRNA expression by quantitative
PCR.  Tal2  mRNA  was  almost  not  detectable  in  Hela  cells.
Expression of Tal2 in HEK293 cells was 2-fold higher than in
Hela cells, in K562 cells Tal2 expression was more than 7-fold
higher. The highest mRNA expression was detected in RAW
264.7  cells  (Figure  1H).  The  mRNA  expression  levels
correlated  with  the  Tal2  protein  amounts  determined  by
western blot with some Tal2 expression in K562 cells and high
expression in RAW cells (Figure 1I). Taken together, our data
show  that  Tal2  is  expressed  in  the  human  erythroleukaemia
cell line K562 and in the mouse monocyte/macrophage cell line
RAW.  Tal2  mRNA  is  upregulated  upon  RANKL  induced
osteoclast differentiation of mouse BMM cells and human U937
cells suggesting a role of Tal2 in this process.
Comparative genomics of the Tal2 locus
The coding region of Tal2 exhibits a high degree of cross
species  conservation.  Between  human  and  mouse  most
amino-acid  differences  are  located  in  the  C-terminus  of  the
protein, whereas the N-terminus with the basic motif and the
helix-loop-helix  motif  are  similar  (Figure  2A,  Megaline-
DNASTAR).  Comparison  of  the  Tal2  protein  sequence
relationship  between  different  species  roughly  reflects  their
phylogenic relationship (Figure 2B). Taken together the degree
of sequence conservation suggested a functional conservation
of Tal2 between the species including mouse and human.
However, we found that the 5’-region in front of the ATG of
Tal2 is divergent between species. We analyzed the 5’-region
of  Tal2  using  the  evolutionary  conserved  region  browser
(ECRbrowser) [32]. Apart from the coding region there are no
evolutionary  conserved  regions  (ECRs)  detected  between
human and chicken (Figure 2C, upper part). The area adjacent
to  the  ATG  is  conserved  between  cow,  mouse,  dog,  rhesus
macaque, chimp and human. Whereas the 5’ region of human
and  chimp  is  almost  identical,  there  is  a  dip  in  conservation
from human towards rhesus macaque (Figure 2C, marked with
an  orange  arrow).  Further  upstream  a  conserved  area  is
detected  between  human,  chimp,  rhesus  macaque  and  cow
(Figure 2C, marked with a star). The total sequence homology
of the 5’-region of the Tal2 gene is low between human and
mouse (Figure 2C).
Subsequently, we scanned the 5’-region of the human Tal2
gene using the repeatmasker software (Smit, AFA, Hubley, R &
Green,  P.  RepeatMasker  Open-3.0.1996-2010  http://
www.repeatmasker.org). We found three repeat elements close
to  the  proximal  promoter  region  of  hTal2,  a  Line-element
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PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e76637Figure 1.  Expression of Tal2.  (A) Expression of murine Tal2 is higher in osteoclasts than the median expression in other cells, for
example macrophages. Screenshot was taken from BioGPS (GeneAtlas MOE430, gcrma). (B) Expression of murine Tal2 measured
by qPCR from bone marrow derived macrophage/monocytes (BMM) cells and BMM cells differentiated towards osteoclasts for three
or six days days with RANKL. Increased Tal2 protein amount was detected at day six upon treatment with RANKL by western blot
(ab85432). (C) Expression of murine TRACP measured by qRT-PCR in RAW cells differentiated towards osteoclasts for three and
six days with RANKL. (D) Expression of murine Tal2 and measured by qRT-PCR in RAW cells upon RANKL treatment for three
days. (E) Expression of TRACP in RAW cells upon RANKL treatment for three days. (F-G) Expression of Tal2 and TRACP in wild
type  U937  cells  and  U937  cells  differentiated  towards  osteoclasts  by  treatment  with  TPA  for  two  days  and  three  days  with  a
combination of M-CSF and RANKL. (H) Comparison of the mRNA expression of Tal2 in different cell lines by qPCR. Expression
values are shown as fold compared to Hela cells. Standard deviations give the error from at least four determinations. (I) Western
blot analysis of Tal2 protein expression in different cell lines (sc-46266).
doi: 10.1371/journal.pone.0076637.g001
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PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e76637Figure 2.  Comparison of the Tal2 locus between species.  (A) Alignment of the human and murine Tal2 protein sequence. The
colour code gives identical and divergent amino-acids, with identical amino-acids marked in red. The position of the basic motif and
the helix-loop-helix motif is shown. (B) Comparison of the Tal2 protein sequence between different species is shown as phylogenic
tree comparing the number of amino acid substitutions and as percent identity. The human sequence represents the 100% value,
highlighted in bold. (C) Comparison of the genomic 5’-regions of Tal2 using the ECR-browser, screenshot. The human sequence
served as the reference genome. The degree of conservation is visualized by the height of the curve belonging to the corresponding
species. Evolutionary conserved regions (ECRs) are shown as a bar in peach colour above the curve. The position of the ATG start
codon is given (black arrow) and a region of homology loss between human and rhesus macaque is marked (orange arrow). A
conserved region, except in mouse, is marked with a star.
doi: 10.1371/journal.pone.0076637.g002
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not  shown).  These  elements  are  also  found  in  chimp  and
rhesus  macaque,  but  not  in  mouse,  suggesting  that  the
introduction of transposable elements is a contributing factor to
the diversity of the 5’ region between human and mouse. This
result  also  raises  the  question  if  promoter  usage  and
expression pattern of Tal2 is identical between the two species.
Interestingly, differences in the 5’-region between human and
mouse are also reflected by the presence of recorded exons in
the  UCSC-genome  browser/database  [35,36].  Whereas  in
human, chimp and rhesus macaque only one exon has been
reported, in mouse exists another exon, more than 6500 bp 5’
of the ATG.
To gain information on the promoter usage at the Tal2 locus
we mapped the 5’-mRNA end by 5’-RACE in RAW, U937 and
K562 cells. Upon PCR amplification of the 5’-regions, the PCR
products were sequenced and aligned to the genomes (Figure
3A). The 5’-RACE revealed different mRNA start sites of Tal2
in  distinct  cell  lines.  In  mouse  RAW  cells  we  detected  one
transcription start site, which is in front of a non-coding exon
approximately 6500 bp upstream of the ATG. This sequence
was named P1 (mP1 in Figure 3B). In U937 cells of human
origin  the  transcription  starts  proximal  to  the  ATG,  with  no
alternative exon (named hP2). Interestingly, in K562 cells we
find two bands, which correspond to two transcriptional start
sites. The higher band matches to an alternative promoter with
an additional exon similar to the RAW cells and the lower band
to a start site close to the ATG similar to U937 cells (Figure
3A). We conclude that in K562 cells Tal2 can be transcribed
from two alternative promoters, which we termed as hP1 and
hP2. Here, the hP1 promoter is similar to the start site used in
the  mouse  RAW  cells  (Figure  3B).  To  further  examine  the
differences between the human and mouse Tal2 promoters, we
compared the promoter activities of the human hP1 and hP2
with the mouse mP1 and mP2 in RAW and K562 cells. For this
we performed luciferase reporter assays with the first 500 bp of
the  hP1,  hP2  and  the  mP1  and  mP2  regions,  respectively.
These regions were cloned in front of the luciferase gene and
the  promoter  activity  measured  in  RAW  and  K562  cells.  In
RAW  cells  hP1  and  hP2  displayed  some  promoter  activity,
however  the  mouse  mP1  promoter  displayed  the  highest
activity, mP2 was almost inactive (Figure 3C). In K562 hP1 and
hP2 showed promoter activity, where as the mouse mP1 was
weakly  active  and  mP2  showed  no  promoter  activity  (Figure
3D).
Taken together our data show differences in the regulation of
Tal2 between human and mouse most notably in humans an
active  promoter  is  close  to  the  ATG  (hP2),  which  is  not
conserved and not active in mouse.
Analysis of the human P2 Tal2 promoter
The P2 promoter of Tal2 is not conserved between human
and mouse and only the human P2 promoter shows activity in
K562 cells and U937 cell. For this reason we chose to further
characterise the P2 promoter of human Tal2. We cloned the 5’-
region of the human Tal2 gene (hTal2) from genomic DNA into
the  pGL4-luciferase  reporter  gene  vector.  Different  length
constructs  were  established,  hTal2(-1600/+16),
hTal2(-1030/+16)  and  hTal2(-495/+16)  (Figure  4A).  All
promoter constructs did not show significant activity in HEK293
cells  but  exhibited  modest  promoter  activity  in
erythroleukaemia K562 cells (Figure 4B-C). In RAW and U937
cells, which have osteoclast differentiation potential, the hTal2-
promoter  was  active  10-  to  14-fold  over  the  empty  vector
(Figure  4D-E)  and  all  promoter  constructs  displayed  similar
activity. The low promoter activity in K562 cells fits well to the
observation that in these cells mostly the hP1 promoter is used.
The relatively high activity in U937 cells is in agreement with
the  use  of  this  hP2  promoter  in  U937  cells  (compare  with
Figure  3).  The  high  activity  in  RAW  cells  could  indicate  that
these  cells  have  all  transcription  factors  present  for  the
activation of the human P2 promoter although in these cells the
mouse P1 promoter is active.
Regulation of the hTal2 hP2 promoter by GATA1 and
PU.1 in K562 cells
We  inspected  the  5´-promoter  region  of  hTal2  for
transcription  factor  binding  sites  using  TESS  [31].  The
hTal2(-495/+16)  promoter  region  contains  potential  binding
sites for the hematopoietic transcription factors PU.1, GATA,
RUNX1,  Tal1  and  CEBP  (Figure  5A).  We  cotransfected  the
hTal2(-495/+16) promoter construct with expression vectors for
the  different  transcription  factors  and  detected  a  robust
induction of promoter activity by PU.1 and GATA1 (Figure 5B).
Subsequently, we mutated the PU.1 site and the first GATA1
site,  respectively.  Mutation  of  the  PU.1  site  led  to  loss  of
activation by PU.1 and mutation of the first GATA1 site led to
decreased activation by GATA1 (Figure 5C). This suggests that
these sites are important for transcription factor binding.
In agreement with the luciferase data we detected binding of
GATA1 and PU.1 to the endogenous hTal2 hP2 promoter by
chromatin immunoprecipitation, verifying that hTal2 is a direct
target gene of GATA1 and PU.1 in K562 cells (Figure 6A). PU.
1 binding was detected at both hP1 and hP2 promoter regions,
but mostly at the hP2 promoter, whereas GATA1 binding was
exclusively  found  at  hP2  (Figure  6A).  Binding  of  RNA-
polymeraseII  was  mostly  detected  at  hP1  and  to  a  lesser
extend at hP2 (Figure 6B), which fits to the RACE data (Figure
3A). When we compared the human and mouse sequence we
found that the PU.1 binding site is not present in the murine
mP2 promoter, however there is a PU.1 binding site in the mP1
promoter of the murine Tal2 gene. Accordingly, in murine RAW
cells  we  detected  PU.1  binding  to  the  mP1  promoter  of  the
mouse Tal2 gene, but not to the mP2 promoter (Figure 6C). In
RAW cells no binding of GATA1 was detected at the mP1 or
mP2  promoter.  Furthermore,  we  found  RNA-polymeraseII
present mostly at the P1 promoter, which is in line with the use
of the P1 promoter in RAW cells (Figure 6D). Taken together,
although the promoter sites differ, PU.1 targets the murine and
the  human  Tal2  gene  and  GATA1  binding  could  only  be
detected in the erythroleukemia cell line K562.
Knockdown of Tal2 influences TRACP expression
Tal2 expression was high in the monocyte/macrophage RAW
cells, which can be induced to differentiate into osteoclast cells.
This is in agreement to the data from the Symatlas expression
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PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e76637Figure 3.  Evaluation of the Tal2 transcriptional start site in human and mouse.  (A) 5’-RACE (rapid amplification of cDNA
ends) defines transcription start sites of Tal2 in distinct cells. 5’-RACE was performed using mRNA from murine RAW, U937 and
K562 cells of human origin. Upon PCR the products were analysed on a gel, sequenced and aligned to the genome. Two different
start  sites  were  defined  and  named  the  P1-promoter  and  the  P2-promoter.  Specific  products  are  marked  with  an  arrow.  (B)
Schematic representation of the human and mouse genomic region of Tal2. The human Tal2 gene has two alternative promoters
hP1 and hP2. hP1 is located at about -6500 bp from the ATG and includes an alternative non-coding exon. In mouse RAW cells the
mP1 promoter is active. The position of primer pairs for ChIP is marked. (C) In a luciferase experiment the promoter activity of the
first 500 bp of the human hP1 and hP2 region was compared with the mouse mP1 and mP2 region in murine RAW cells. (D)
Luciferase experiment comparing the promoter activity of the first 500 bp of the human hP1 and hP2 region with the mouse mP1
and mP2 region in human K562 cells. Values are given as fold related to the luciferase values gathered with the empty pGL4 vector.
Error bars give the standard deviation of four determinations.
doi: 10.1371/journal.pone.0076637.g003
Tal2 Expression Is Regulated from Two Promoters
PLOS ONE | www.plosone.org 7 September 2013 | Volume 8 | Issue 9 | e76637Figure  4.    Analysis  of  the  human  Tal2  promoter  activity  in  different  cell  lines.    (A)  Different  length  promoter  luciferase
constructs  were  established.  The  position  of  the  cloned  fragments  with  respect  to  to  the  ATG  is  given.  The  fragments  were
numbered from A to C. (B-E) Activity of the different length promoter constructs in HEK293, K562, RAW and U937 cells. Values
were calculated as relative luciferase light units corrected for transfection efficiency by beta-galactosidase activity and are shown as
fold over the activity of the empty pGL4 vector. Standard deviations were calculated from at least four determinations.
doi: 10.1371/journal.pone.0076637.g004
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PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e76637Figure 5.  The human Tal2 promoter is activated by GATA1 and PU.1. (A).  The sequence of the human Tal2 P2-promoter is
shown  and  identified  potential  transcription  factor  binding  sites  are  marked  in  colour.  (B)  PU.1  and  GATA1  activated  the
hTal2(-495/+16)  promoter  in  HEK293  cells.  (C)  Mutation  of  the  PU.1  and  GATA1  site,  respectively,  diminish  activation  by  the
transcription factor. Wild type or mutant promoter construct were cotransfected with the given transcription factor and luciferase
activity measured after 48 hours. Error bars give the standard deviation of at least six evaluations. The mutated sites are underlined.
doi: 10.1371/journal.pone.0076637.g005
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PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e76637Figure 6.  Tal2 is a direct target of PU.1 and influences expression of the osteoclast differentiation gene TRACP.  (A)
Chromatin-immunoprecipitation (ChIP) of GATA1 and PU.1 on the endogenous hTal2 promoter in K562 cells. PU.1 bind to some
extend to the hP1 and hP2 promoter, GATA1 binding is detected at the hP2 promoter. (B) Chromatin immunoprecipitation in K562
cells using an antibody against RNA-polymeraseII shows binding of RNA-polymeraseII to hP1 but less to hP2 of the human Tal2
gene. (C) Chromatin immunoprecipitation in RAW cells using an antibody against PU.1 shows binding of PU.1 to mP1 but to a less
extend  to  the  mP2  region  of  the  murine  Tal2  gene.  GATA1  does  not  bind  to  the  mP1  or  mP2  promoter.  (D)  Chromatin
immunoprecipitation in RAW cells using an antibody against RNA-polymeraseII shows binding of RNA-polymeraseII to mP1 but less
to mP2 of the murine Tal2 gene. (E) Knockdown of Tal2 decreases TRACP expression. qRT-PCR was performed from RAW cells
upon knockdown of Tal2 by shRNA. Standard deviations give the error from at least four determinations. (F) Western blot analysis
showing the Tal2 knock down on the protein level in RAW cells.
doi: 10.1371/journal.pone.0076637.g006
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cells  compared  to  other  tissues  (Figure  1).  To  gather
information if Tal2 is involved in osteoclast related functions,
we performed an shRNA mediated knockdown of Tal2 (Figure
6E). Tal2 knock down was detectable at the mRNA and protein
level  (Figure  6E,F).  When  we  analyzed  the  expression  of
genes associated with osteoclast differentiation in the shTal2
cells we found a significant decrease of the expression of the
tartrate resistant acid phosphatase gene TRACP (Figure 6E).
This suggests that Tal2 takes part in the control of the gene
expression program during osteoclastogenesis.
Discussion
Expression of Tal2
Ectopic Tal2 expression is associated with acute lymphatic
T-cell leukaemia in humans. However Tal2 expression was not
reported  in  normal  hematopoietic  cells  of  human  or  mouse
origin.  In  the  murine  model  Tal2  expression  was  detected
mostly in the brain but not in hematopoietic cells and in the
Tal2  knockout  mice  no  overt  hematopoietic  defect  was
detected.  Our  data  show  that  Tal2  mRNA  and  protein  is
expressed in a number of cell lines of myeloid origin such as
the  human  erythroleukaemia  cell  line  K562  and  the  murine
monocyte/macrophage cell line RAW. Furthermore, we found
Tal2  also  in  mouse  primary  bone  marrow  monocyte/
macrophage  (BMM)  cells.  We  detected  upregulation  of  Tal2
during osteoclast differentiation of RAW cells and BMM cells of
murine  origin  and  in  U937  cells  of  human  origin.  This  is  in
agreement  with  our  finding  that  the  human  Tal2  promoter  is
active  in  cells  with  osteoclast  differentiation  potential.  This
indicates  that  Tal2,  similar  to  its  family  member  Tal1,  has  a
functional role in osteoclast differentiation [16].
Differences between human and murine Tal2
The degree of sequence conservation on the protein level
suggests a functional conservation between species, including
mouse and human. Accordingly, the analysis of Tal2 function
and expression in the mouse e.g. expression in the brain and
no expression in the hematopoietic system, was translated to
the  human  system  in  most  publications  regarding  Tal2.  We
found that human Tal2 can be transcribed from two alternative
promoters hP1, which is about 6500 bp upstream from the ATG
and hP2, which is proximal to the ATG. Promoter usage seems
to  be  cell  type  dependent.  In  U937  cells  we  only  detected
transcripts from the hP2 promoters, whereas in K562 cells both
promoters  are  used,  but  the  hP1  promoter  seemed  to  have
higher activity. In mouse RAW cells only transcripts from the
mP1  promoter  were  detected  and  the  mP2  promoter  was
inactive in contrast to the hP2 promoter.
Interestingly, in human K562 cells the region proximal of the
ATG is used as a promoter and includes a PU.1 binding site,
this site is not conserved and not used in the mouse. In K562
erythroleukaemia  cells  we  detected  PU.1  binding  at  the  hP1
and hP2 site and additionally GATA1 binding was detected at
the hP2 promoter. This could indicate that the hP2 promoter
plays a role in cells where also PU.1 and GATA1 are involved
such as erythroid/megakaryocytic differentiation.
In murine RAW cells the mP2 region has no promoter activity
and  neither  PU.1  nor  GATA1  binding  could  be  detected.
However, at the mP1 promoter PU.1 binding was detected in
front of an additional non-coding exon 6500bp upstream of the
ATG. In contrast to K562 cells GATA1 binding was not found at
the  mP1  or  mP2  promoter  in  RAW  cells.  The  differences
between  human  and  mouse  could  be  caused  by  the
introduction  of  transposable  elements  5’  of  the  ATG  in  the
human  sequence  as  we  find  three  of  these  elements  in  the
human gene but not in the mouse. Interestingly transposons
are frequently found in regulatory regions like promoters [37].
Our finding that PU.1 binds to the Tal2 promoter in mouse
and  human  cells  is  in  line  with  our  observation  that  Tal2  is
expressed in the myeloid lineage, because PU.1 is a master
regulator of myeloid differentiation [38]. Moreover, PU.1 plays a
crucial  role  in  osteoclast  differentiation  [39,40]  and  gene
expression [41,42,43]. In human an additional hP2 promoter is
active,  which  harbours  binding  sites  for  hematopoietic
transcription factors such as PU.1, GATA1 and RUNX1. This is
a hint that expression of Tal2 might be different in human and
mouse especially in cells where the hP2 promoter is activated.
Potential molecular function of Tal2
Upon  knockdown  of  murine  Tal2  we  observed  a  reduced
expression of TRACP, which encodes for an important enzyme
of  osteoclast  function  and  differentiation.  Other  important
osteoclast  specific  genes  like  DC-STAMP  and  CTSK  remain
unchanged. For further analysis of Tal2 function in osteoclast
differentiation  a  conditional  Tal2  knockout  in  the  osteoclast
lineage  would  be  highly  desired.  The  finding  that  Tal2  can
influence  the  expression  of  osteoclast  genes  raises  the
question  how  Tal2  acts  at  the  molecular  level  on  gene
expression. Because Tal2 is only a small protein consisting of a
conserved bHLH and a less conserved short C-terminus with
no  defined  repressor  or  activator  domain,  we  speculate  that
Tal2  could  function  by  dimerising  to  other  bHLH  factors  like
E47 or Tal1 in osteoclast differentiation. An important hint may
come  from  data  showing  that  Tal2  is  not  able  to  bind  DNA
alone but may act by dimerisiation with other bHLH protein like
E47 [44]. In this regard our recent finding that Tal1 influences
osteoclast specific genes [16] would be in line with a function of
Tal2 in conjunction with Tal1.
In  conclusion  Tal2  expression  is  upregulated  during
osteoclast differentiation in the mouse and human system and
may  take  part  in  the  regulation  of  osteoclast  genes.  Despite
diversity in promoter usage, PU.1 binding to mouse and human
Tal2  regulatory  elements  is  maintained.  However,  other
aspects  of  Tal2  expression  regulation  might  be  different
between species. Tal2 expression is linked to T-cell leukaemia,
we also detected Tal2 expression in the erythroleukaemia cell
line  K562,  and  thus  it  might  be  involved  in  this  form  of
leukaemia. The further analysis of Tal2 expression and function
in the human system should reveal differences to the mouse
model and shed light on the potential role of Tal2 in osteoclast
related disease and leukaemia.
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